此次收购使GSK能够整合Elsie的寡核苷酸发现、合成和递送技术,以增强GSK平台的研发能力。通过GSK于2023年7月与Elsie达成的研究合作协议,GSK得以探索和验证Elsie的寡核苷酸技术。通过Elsie平台生成的数据,结合GSK在人工智能和机器学习方面的专业知识,将支持未来GSK寡核苷酸设计预测模型的开发。 此次收购符合GSK将科学和技术相...
/20272/session/609 [2] GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health. Retrieved April 18, 2023 from https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage...
此次收购使GSK能够整合Elsie的寡核苷酸发现、合成和递送技术,以增强GSK平台的研发能力。通过GSK于2023年7月与Elsie达成的,GSK得以探索和验证Elsie的寡核苷酸技术。通过Elsie平台生成的数据,结合GSK在人工智能和机器学习方面的专业知识,将支持未来GSK寡核苷酸设计预测模型的开发。 此次收购符合GSK将科学和技术相结合的策略,...
中国药物临床试验登记与信息公示平台官网近日公示, Bellus Health公司已经登记启动了一项国际多中心(含中国)3期临床研究,以评估BLU-5937治疗难治性慢性咳嗽(包括不明原因的慢性咳嗽)的安全性和有效性。 公开资料显示,BLU-5937(camlipixant)是一款选择性口服P2X3受体拮抗剂。2023年4月,葛兰素史克(GSK)宣布已与Bellus...
*COVID-19 solutions defined on page 53 of FY 2023 press release You might also like Quarterly results Discover our latest financial performance announcement and search for historical quarterly results materials Behind the science magazine Explore innovations from inside and outside our labs. Go #Behin...
28 June 2023 Issued: London, UK For media and investors onlyGSK completes acquisition of BELLUS HealthDownload PDF of press release (PDF - 162.4KB) GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a ...
utm_source=CI&utm_medium=PressRelease&utm_code=qkvctb&utm_campaign=1819785+-+Oligonucleotide+Synthesis+Global+Market+Report+2023%3a+Increased+Pharma+R%26D+to+Spur++Growth&utm_exec=como322prd#product--adaptive [2]https://www.fiercebiotech.com/biotech/no-regrets-gsk-turning-its-back-cell-...
PRESS RELEASE 2023 forecast: FDA revamps cancer drug approvals 21 Dec 2022 // FIERCEPHARMA GSK Strikes $3.3B Oligonucleotide Pact with Wave Life Sciences 14 Dec 2022 // BIOSPACE GSK announces new global headquarters in central London 13 Dec 2022 // ...
utm_source=CI&utm_medium=PressRelease&utm_code=qkvctb&utm_campaign=1819785+-+Oligonucleotide+Synthesis+Global+Market+Report+2023%3a+Increased+Pharma+R%26D+to+Spur++Growth&utm_exec=como322prd#product--adaptive [2]https://www.fiercebiotech.com/biotech/no-regrets-gsk-turning-its-back-cell-...
23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visitwww.23andMe.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the...